- In March 2025, Thermo Fisher Scientific, announced the launch of its next-generation PCR reagents for advanced DNA and RNA analysis. These reagents offer improved sensitivity, faster amplification, and higher throughput, enabling researchers to achieve more accurate and reproducible results in genomics, clinical diagnostics, and personalized medicine. The new PCR reagents are designed to meet the growing demand for precise and rapid genetic analysis in life sciences research
- In January 2025, Bio-Rad Laboratories, Inc., introduced its new line of single-cell RNA sequencing reagents. These reagents enable high-resolution analysis of gene expression in individual cells, providing deeper insights into cellular functions, disease mechanisms, and therapeutic responses. The innovative reagents are expected to enhance the company's position in the rapidly growing single-cell analysis market
- In November 2024, Merck KGaA launched its new CRISPR genome editing reagents, aimed at accelerating gene editing research and therapeutic development. These reagents are designed to offer precise and efficient genome modifications, supporting advancements in personalized medicine and biotechnology research. The launch reflects Merck's commitment to advancing life sciences research and expanding its biotechnology product portfolio
- In October 2024, Agilent Technologies announced the release of its next-generation HPLC reagents for biopharmaceutical analysis. These reagents are specifically designed to improve the accuracy and speed of protein purification and characterization, meeting the increasing demand for high-quality biologics. The new HPLC reagents are part of Agilent's broader strategy to support the rapidly expanding biopharmaceutical industry
